For seamless registration, login with your Medscape membership account. If you are not logged in, you can register as a guest.
The treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC) is rapidly shifting. A sizable proportion of patients progress to castration-resistant disease within 12 months of standard therapy, highlighting the urgent need for intensifying treatment beyond androgen deprivation therapy (ADT).
In this livestreamed discussion, renowned experts Dr Neal Shore, Dr Rana R. McKay, and Dr Sarah Caulfield take a deep dive into the latest evidence supporting treatment intensification strategies in mHSPC and share practical tools for managing combination therapies, including potential drug-drug interactions. Grounded in data and built for the interprofessional care team, this activity translates evolving science into actionable clinical insights that can elevate your practice.
Director, START Carolinas/Carolina Urologic Research Center, Head of Genitourinary GU Oncology START Research, Atlantic Urology Clinics Urology Specialists, Myrtle Beach, South Carolina
Rana R. McKay, MD, FASCO
Panelist
Professor of Medicine, Urology, and Radiation Medicine and Applied Sciences, Moores Cancer Center, University of California San Diego, La Jolla, California
Sarah Caulfield, PharmD, BCOP
Panelist
Oncology Pharmacy Specialist, Genitourinary Clinic, Emory Healthcare, Winship Cancer Institute, Emory University, Atlanta, Georgia